Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Aurobindo Pharma Ltd Performance

Today's Low
1,079.00
arrowIcon
Today's High
1,109.00
52 Wk Low
576.15
arrowIcon
52 Wk High
1,177.10


Open

1109

Traded Value (Cr)

141.80 Cr

Prev. Close

1114.5

VWAP

1089.45

Volume

20,27,734

Face Value

1

Aurobindo Pharma Ltd Fundamentals

Market Cap
₹ 64,965 Cr
P/E Ratio (TTM)
23.11
P/B Ratio
2.30
Debt to Equity
0.24
ROE
8.25 %
EPS (TTM)
47.97
Dividend Yield
0.68%
Book Value
481.09

Click here to know more about Fundamentals

Aurobindo Pharma Ltd F&O

Aurobindo Pharma Ltd Option Chain

Aurobindo Pharma Ltd Financials

Aurobindo Pharma Ltd Financials

Aurobindo Pharma Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 51.83 % 51.83 % 51.83 % 51.83 %
FII 18.02 % 20.72 % 22.45 % 24.13 %
Mutual Funds 17.83 % 14.70 % 11.27 % 8.37 %
Others 6.81 % 7.11 % 8.29 % 8.65 %
Retail 5.52 % 5.64 % 6.15 % 7.01 %

Promoters

51.83%

FII

18.02%

Mutual Funds

17.83%

Others

6.81%

Retail

5.52%

Promoters

51.83%

FII

20.72%

Mutual Funds

14.70%

Others

7.11%

Retail

5.64%

Promoters

51.83%

FII

22.45%

Mutual Funds

11.27%

Others

8.29%

Retail

6.15%

Promoters

51.83%

FII

24.13%

Mutual Funds

8.37%

Others

8.65%

Retail

7.01%

Resistance and Support

₹1,023.77

PIVOT

resistance-arrow
Resistance
First Resistance₹1,035.283
Second Resistance₹1,042.317
Third Resistance₹1,053.833
support-arrow
Support
First Resistance₹1,016.733
Second Resistance₹1,005.217
Third Resistance₹998.183
RSI53.733
MACD34.935
ADX13.873
CCI13.228

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day2,027,734592,89945.45
Week1,842,1541,306,83965.84
1 Month1,770,023870,67248.32
6 Months2,027,7341,274,71862.86

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry and it became a public venture in 1992. In the same year 1992, another unit was also set up for the manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad through another company, namely Chaitanya Organics Pvt. Ltd. Later in 1994-95, it was merged with the company. The commercial production of the pharmaceutical formulation unit was started in April of the year 1994. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. Glaxo (India), the Indian subsidiary of the UK-based multinational came to an alliance with the company to meet its global bulk drug requirements during the year 1997. In the year 1998, the company had launched new formulations like auronim Suspension in the paediatric segment. During 1999-2000, the company diversified its product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti - virals in addition to macrolides, anti-ulcerants, quinolones, semi-synthetic penicillins and formulations for domestic and export market. APL made Joint Ventures for formulations business in US, with an investment of a million in the year 2000. Sri Chakra Remedies Ltd was amalgamated with the company in the identical year of 2000. The Company has launched an exclusive anti-viral division Immune during the year 2001 to educate and to provide preventive drug care for HIV/AIDS patients in the country. APL had launched two more drugs in the same year of 2001, namely Efavirenz (Viranz) and Nelfinavir (NELVEX) for the treatment of AIDS. During the year 2001-02 the company acquired 79% stake in Ranit Pharma Company under the same management. Ranit Pharma and Calc Private Ltd were amalgamated with APL as at 1st April of the year 2002. Citadel Aurobindo Biotech Ltd, a 50:50 Joint Venture (JV) Company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM' in the year 2003. During the same year the JV was happened between APL and Shanxi Tongling Pharmaceuticals Company, as an upshot formulated the JV Company under the name of Aurobindo Tongling (Datong) pharmaceuticals Ltd, China, for manufacture of pharmaceutical products to the local market. APL's 100% subsidiary company in China had commenced its commercial production during the year 2003-2004, which was formulated to procure raw material 6 APA at an economical cost. APL also launched the second JV Company in US for the purpose of Research and Development. During the year 2004, the company received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology. During the year 2004-05 the company acquired a sterile plant of Dee Pharma for the consideration of Rs.38 million which located at Bhiwadi in Rajasthan. US FDA part of Department of health and human science approved the Unit VIII facility of the company in the year of 2005 as a site to manufacture of APIs for the US Market. Also in the same year APL had received US FDA clearance for AIDS drug. The State Labour Department of the Government of Andhra Pradesh has awarded the 'Best Management Award' for the year 2005 for the Company's contributions towards community development, harmonious employee relations and their welfare. During the year 2005-06, the company made a strategic entry with its generic formulations in the premium markets of USA & Europe, participated in the PEPFAR program initiated by the Government of USA and consolidated its strengths in the less regulated and emerging markets. Also in same year APL had acquired the UK based Milpharm Limited, the generic formulation pharmaceutical company engaged in marketing generic formulations mainly in the UK market. During March of the year 2007, the US FDA has granted final approval for the Company's Didanosine Oral Suspension (Pediatric Powder) 10 mg / ml. As at June 13th of the year 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects this pace and leadership. Artistic lines intersect to make up the company's initials 'A' and 'P'. The way the initials 'A' and 'P' have joined conveys the spirit of 'partnership' with the company's business. The Hon'ble High Court of Andhra Pradesh has approved the scheme of arrangement for merger of APL Life Sciences and Senor Organics into the company and the utilisation of share premium account of the company during June of the year 2007. APL concluded a strategic deal, for acquisition of intellectual property & marketing suthorizations, with TAD Italy, a generic company registered in Italy during March of the year 2008. This acquisition will give Aurobindo an access to more than 70 ready to market products, which will fast track Aurobindo's entry into the Italian generic market. As a part of this deal, APL also acquired high profile OTC brands - Mapooro and Carmiooro from TAD in same period of the year 2008. On 6 September 2010, Aurobindo Pharma announced that it has entered into licensing and supply agreements with AstraZeneca, one of the world's leading biopharmaceutical companies, to supply several solid dosage and sterile products for emerging markets. On 11 January 2011, Aurobindo Pharma announced that it had entered into a definitive agreement with China National Pharmaceutical Group Corporation (Sinopharm) to divest in its subsidiary company Aurobindo (Datong) Bio Pharma Co Ltd, China (ADBPL), subject to regulatory approvals. ADBPL is engaged in manufacturing of 6APA, a derivative of Penicillin-G. Aurobindo Pharma decided to retain 19.50% stake in ADBPL so as to ensure uninterrupted supply of raw materials at competitive price. On 7 September 2011, Aurobindo Pharma announced the establishment of an equal joint venture in Russia with OJSC DIOD to manufacture and sell pharmaceuticals in Russia, Belarus and Kazakhstan. On 1 April 2014, Aurobindo Pharma announced the completion of the acquisition of certain commercial operations in Western Europe from Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The agreement to acquire the Actavis operations was announced in January 2014. On 5 December 2014, Aurobindo Pharma announced the completion of acquisition of assets of nutritional supplement maker, Natrol Inc. and other affiliate entities (Natrol) through its wholly owned subsidiary Aurobindo Pharma USA Inc. (APUSA). On 12 November 2014, APUSA emerged as the highest and best bidder to acquire assets of Natrol under the auction process by the United States Bankruptcy Court for the District of Delaware. APUSA acquired the manufacturing assets, personnel, commercial infrastructure including the well established nutraceuticals brands in USA of Natrol along with an agreement to take on certain liabilities, with a bid of $132.5 million. On 25 November 2016, Arrow Generiques SAS, a French subsidiary of Aurobindo Pharma Ltd, announced the signing of an agreement to acquire the right, title and interest in its products Calcium and Calcium Vitamin D3 in France, including the use of the OROCAL trademark, from Teva Pharmaceutical Industries. On 7 January 2017, Aurobindo Pharma announced the signing of a binding agreement by and through its wholly owned step-down subsidiary, Agile Pharma B.V, Netherlands, to acquire Generis Farmaceutica SA, a Portuguese pharmaceutical company, for a total consideration 135 million Euro, including net working capital of 21.7 million Euro. On 9 February, 2017, Aurobindo Pharma announced the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. As on 31 March 2018,the company has 56 subsidiary companies under its roof. During the FY2018,the company launched 38 products including 6 injectables in the US. As on 31 March 2018, the Company filed 478 ANDAs on a cumulative basis. During the year 2018, Agile Pharma BV, a step down subsidiary of the Company acquired Generis Farmaceuita SA and its 4 subsidiaries viz. Mer Medicamentos, Portugal, Generis Phar, Portugal, Pharma APS, Portugal and Generis Mozambique, Portugal. Post acquisition of Generis Farmaceuita SA, Portugal, as part of restructuring of operations in Portugal, Aurobindo Pharma (Portugal) Unipessoal Limitada and Aurovitas, Unipessoal LDA, Mer Medicamentos, Lda, Farma APS and Generis Mozambique have been either merged with Generis Farmacutica SA or liquidated. On May 28, 2019 the Board of Directors had accorded its approval for the draft scheme for merger of Company's 5 (Five) Wholly Owned Subsidiaries (i.e. APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and APL Healthcare Limited) and 1 (one) step-down wholly owned subsidiary (i.e. Silicon Life Sciences Private Limited) with the Company. No shares of the Company will be issued as consideration for the said amalgamation and the shares held by the Company in its wholly owned subsidiaries and step-down wholly owned subsidiary shall stand cancelled. The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). Pursuant to the orders dated 30 September 2019, the required approvals of the Shareholders and unsecured creditors were obtained at the meetings held on 30 November 2019. The Company has made an investment of Rs 150 million in Synergy Remedies Private Limited (Synergy), a Tirupathi based pharma company and acquired 19.9% holding in the said company. The objective of this acquisition was to ensure assured supplies of some of the APIs and intermediates. During the FY2020,the Company through Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company, acquired certain R&D assets from Profectus BioSciences Inc'., USA, a clinicalstage vaccine development company in the design and development of preventive and therapeutic vaccines for an upfront cash consideration US$11.29 million with potential earn outs on achieving certain milestones. This acquisition provided access to Proprietary & Innovative technology platforms for Prophylactic use & Therapeutic use along with Global R&D center to develop newer vaccines from basic discovery research into FDA-approved product. The Board of Aurobindo Pharma Limited on 3rd June 2020 had approved the transfer of Company's Biosimilar business and related R&D manufacturing facilities (Unit-17 and R&D-3) situated at survey No. 77 & 78, Indrakaran Village, Kandi Mandai, Sanga Reddy District, Telangana to its newly incorporated wholly owned subsidiary CuraTeQ Biologics Private Limited (CuraTeQ), through a slump sale. On 25 October 2020, pursuant to the Board's approval, the Group entered into a definitive agreement to dispose of business assets of a wholly-owned step-down subsidiary, Natrol LLC, United States of America as a going concern with related assets, liabilities, products, brands and employees for a cash price of USD 550 million. The Board in its meeting held on 16 October 2020 decided to enter into a share purchase agreement to acquire 100% equity share capital of MViyes Pharma Ventures Private Limited. MViyes Is holding 32.18% shareholding In Eugia Pharma Specialties Limited, a joint venture company In which the Parent Company, through its wholly-owned subsidiary company, is holding 67.82%. By this acquisition, both Eugia Pharma Specialities Limited and MViyes Pharma Ventures Private Limited have become wholly owned subsidiaries. During the FY2021,the company has incorporated WYTELLS PHARMA PRIVATE LIMITED w.e.f 20 February 2021, as a subsidiary to Eugia Pharma Specialties Limited, India. During the period 2021-22, Aurobindo Pharma Gmbh Germany merged with Puren Pharma GmbH w.e.f. October 1, 2021. CuraTeQ Biologics GmbH was Liquidated w.e.f. October 7, 2021 and Longxiang Pharma Taizhou Co. Ltd. was Liquidated w.e.f. August 31, 2021. The Company has transferred 100% stake in Auro Cure Private Limited, a wholly-owned subsidiary of Company to Eugia Pharma Specialities Limited and consequently, Auro Cure Private Limited has become wholly owned step-down subsidiary of the Company. It transferred business undertaking comprised in Unit-16 of the Company, on a going concern basis, to Wytells Pharma Private Limited, a wholly-owned step-down subsidiary of the Company. i.e. , Wytells Pharma Private Limited is a 100% subsidiary of Eugia Pharma Specialities Limited which in turn is a wholly-owned subsidiary of the Company. It transferred vaccines business undertaking comprised in Unit-18, on a going concern basis, to Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company; and also transferred equity shares of Tergene Biotech Private Limited, a subsidiary, to Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company. The Board of Directors of the Company at its meeting held on July 1, 2021, has approved the transfer of business undertaking comprised in Unit·4, on an on-going concern basis, to Eugia Pharma Specialities Limited, a wholly-owned subsidiary of the Company. During the year 2022, Auro PR Inc, a subsidiary of Helix Healthcare B.V. Netherlands, acquired certain properties including rights, title and interest in the assets and liabilities owned by Mylan LLC USA. The Company acquired the business of Veritaz Healthcare Limited on slump sale basis for a consideration of Rs. 1,710 million on March 28, 2022, which operates in the pharmaceutical industry in India and sells branded generic formulations and other health care related products. During the period 2022-23, Auro PR I LLC (formerly known as Mylan LLC) Merged with Auro PR Inc w.e.f. May 23, 2022. Theranym Biologics Private Limited was incorporated as wholly owned subsidiary of Curateq Biologics Private Limited w.e.f. September 22, 2022. PT Aurogen Pharma Indonesia was incorporated as a wholly owned stepdown subsidiary (99% held by Helix Healthcare BV and 1% held by Agile Pharma BV) w.e.f. July 1, 2022. 51% share capital of GLS Pharma Limited was acquired and it became a subsidiary with effect from August 17, 2022. The Company launched 34 products in USA, including 17 injectable products in 2023. It completed treatment phase of trastuzumab, a biosimilar to Herceptin, in a Phase 3 study comprising 690 metastatic breast cancer patients during 2022-23. It acquired 51% stake in the domestic oncology business of GLS Pharma Limited.

Managing Director

Founded

1986

NSE Symbol

AUROPHARMA

Aurobindo Pharma Ltd Management

NameDesignation
K RagunathanChairman & Independent Directo
Kambam Nityananda ReddyExecutive Director
M SivakumaranExecutive Director
M Madan Mohan ReddyExecutive Director
P V Ramprasad ReddyNon Executive Director
Savita MahajanIndependent Non Exe. Director
Girish Paman VanvariIndependent Non Exe. Director
P Sarath Chandra ReddyIndependent Non Exe. Director
Santanu MukherjeeIndependent Director
Deepali Pant JoshiAdditional Director

Aurobindo Pharma Ltd News

Auro Pharma’s Andhra Pradesh facility gets 3 USFDA observations
The pharmaceutical company announced that the US drug regulator has concluded its inspection at the new injectable facility in Andhra Pradesh, with three observations.
Aurobindo Pharma reports accident in Unit 6 of Apitoria Pharma
Aurobindo Pharma appoints senior management personnel
Barometers trade lower; pharma shares decline for 2nd day
Auro Pharma rises on USFDA nod for nasal spray
Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray.
Auro Pharma’s arm restarts distribution of aseptic products
Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma has started re-distribution of aseptic products manufactured at Unit III, a formulation manufacturing facility located in Telangana, which was temporarily stopped.
Aurobindo Pharma jumps on USFDA nod for Fingolimod capsules
Aurobindo Pharma rallied 4.83% to Rs 1,076.10 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod capsules.
Volumes spurt at Aurobindo Pharma Ltd counter
Aurobindo Pharma Ltd notched up volume of 21235 shares by 10:00 IST on BSE, a 0.6 fold spurt over two-week average daily volume of 35291 shares
Auro Pharma's Telangana injectable facility gets 7 USFDA observations
The drug maker announced that the US drug regulator had concluded its inspection at the injectable facility of Eugia SEZ with seven observations.
USFDA completes inspection of Eugia SEZ's injectable facility

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,65,370 Cr
₹ 1,522.80
(0.42 %)
88.68
CIPLA₹ 1,08,655 Cr
₹ 1,345.75
(-0.12 %)
33.03
DRREDDY₹ 99,137 Cr
₹ 5,942.85
(-0.24 %)
24.91
DIVISLAB₹ 97,472 Cr
₹ 3,671.70
(-1.00 %)
71.41
MANKIND₹ 93,635 Cr
₹ 2,337.45
(-2.43 %)
56.69

Aurobindo Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Aurobindo Pharma Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Aurobindo Pharma Ltd's share price is ₹1,087.05 as of April 19, 2024

Aurobindo Pharma Ltd's P/E ratio is 23.11 times as of April 19, 2024.

Aurobindo Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 2.30, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Aurobindo Pharma Ltd's market is 64,966 Cr as on April 19, 2024.

The current financial records of Aurobindo Pharma Ltd show a 8.25% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Aurobindo Pharma Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Aurobindo Pharma Ltd's 52-week high and low as of April 19, 2024 are ₹1109 and ₹1079 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Aurobindo Pharma Ltd stands at 51.83%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 20.72% to 18.02%.